IL207220B - Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans - Google Patents

Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Info

Publication number
IL207220B
IL207220B IL207220A IL20722010A IL207220B IL 207220 B IL207220 B IL 207220B IL 207220 A IL207220 A IL 207220A IL 20722010 A IL20722010 A IL 20722010A IL 207220 B IL207220 B IL 207220B
Authority
IL
Israel
Prior art keywords
medicament
age
prevention
preparation
treatment
Prior art date
Application number
IL207220A
Other languages
English (en)
Hebrew (he)
Other versions
IL207220A0 (en
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of IL207220A0 publication Critical patent/IL207220A0/en
Publication of IL207220B publication Critical patent/IL207220B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL207220A 2008-02-11 2010-07-26 Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans IL207220B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Publications (2)

Publication Number Publication Date
IL207220A0 IL207220A0 (en) 2010-12-30
IL207220B true IL207220B (en) 2018-04-30

Family

ID=40521846

Family Applications (2)

Application Number Title Priority Date Filing Date
IL207220A IL207220B (en) 2008-02-11 2010-07-26 Use of a synthetic retinal derivative for the preparation of a medicament for the prevention or treatment of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans
IL258356A IL258356A (en) 2008-02-11 2018-03-26 Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL258356A IL258356A (en) 2008-02-11 2018-03-26 Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans

Country Status (14)

Country Link
US (7) US8324270B2 (https=)
EP (1) EP2252276B1 (https=)
JP (3) JP6022746B2 (https=)
KR (2) KR101810381B1 (https=)
CN (1) CN101969938A (https=)
AU (1) AU2009213138B2 (https=)
BR (1) BRPI0908154A2 (https=)
CA (2) CA3018374A1 (https=)
IL (2) IL207220B (https=)
MX (1) MX337656B (https=)
NZ (3) NZ587376A (https=)
RU (1) RU2565448C2 (https=)
WO (1) WO2009102418A1 (https=)
ZA (1) ZA201005434B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2009102418A1 (en) * 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
CN102612375B (zh) * 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN107308143A (zh) * 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
JP6576636B2 (ja) * 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2021062022A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN116056691A (zh) * 2020-06-09 2023-05-02 典晶生物医药科技(苏州)有限公司 使用每日低剂量的类视黄醇化合物治疗视觉障碍的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) * 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
WO2000068354A1 (en) 1999-05-07 2000-11-16 Chemlink Laboratories Llc Window cleaner tablet
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
CN1455780A (zh) 2001-01-11 2003-11-12 株式会社开备传 新视黄醇衍生物、其制备方法和用途
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003082081A2 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
NZ587006A (en) * 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US20080275133A1 (en) 2004-09-30 2008-11-06 University Of Calfornia-San Francisco Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
US20160331713A1 (en) 2016-11-17
WO2009102418A1 (en) 2009-08-20
US20130072557A1 (en) 2013-03-21
KR20100126358A (ko) 2010-12-01
US9855239B2 (en) 2018-01-02
JP2014221828A (ja) 2014-11-27
JP5934304B2 (ja) 2016-06-15
CA2714530C (en) 2018-09-25
IL258356A (en) 2018-05-31
CA3018374A1 (en) 2009-08-20
CA2714530A1 (en) 2009-08-20
NZ587376A (en) 2012-06-29
US20100035986A1 (en) 2010-02-11
JP6022746B2 (ja) 2016-11-09
US9233091B2 (en) 2016-01-12
KR101810381B1 (ko) 2017-12-19
EP2252276A1 (en) 2010-11-24
CN101969938A (zh) 2011-02-09
MX2010008847A (es) 2010-11-30
AU2009213138B2 (en) 2014-11-06
JP2011511789A (ja) 2011-04-14
ZA201005434B (en) 2011-11-30
NZ617701A (en) 2015-06-26
NZ600498A (en) 2014-01-31
US8324270B2 (en) 2012-12-04
US20130072561A1 (en) 2013-03-21
JP2016190852A (ja) 2016-11-10
US20130072558A1 (en) 2013-03-21
BRPI0908154A2 (pt) 2015-08-11
US20180098955A1 (en) 2018-04-12
EP2252276B1 (en) 2019-03-27
US20190133986A1 (en) 2019-05-09
JP6272943B2 (ja) 2018-01-31
KR20160092032A (ko) 2016-08-03
RU2010137842A (ru) 2012-03-20
AU2009213138A1 (en) 2009-08-20
US9408821B2 (en) 2016-08-09
IL207220A0 (en) 2010-12-30
RU2565448C2 (ru) 2015-10-20
MX337656B (es) 2016-03-14

Similar Documents

Publication Publication Date Title
IL258356A (en) Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
IL234624A0 (en) Compounds for use as a drug to treat a solid tumor in a patient
ZA200905962B (en) Combination therapy for treatment of immune disorders
IL217777A (en) A peptide for the preparation of pain medication
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
IL221276A (en) Combination with Sigma ligand and opioids or opiates for prevention or treatment of pain that develops as a result of surgery
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2013098416A3 (fr) Composes anti-douleur
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
IL207965A (en) Compounds to treat or prevent pain
PT2379066E (pt) Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
IL240394B (en) Use of alemtuzumab to prepare a drug for use as a secondary treatment in multiple sclerosis
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0822486D0 (en) Compounds for use in the treatment of pain
ZA201004520B (en) N-phenyl-imidazo[1,2-a]pyridine-2-carboxamide compounds,preparation thereof and therapeutic application thereof
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL216717A (en) Use of benzidamine in the manufacture of a drug for the treatment of p40-dependent diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed